vs
Side-by-side financial comparison of BIOMERICA INC (BMRA) and Alpha Teknova, Inc. (TKNO). Click either name above to swap in a different company.
Alpha Teknova, Inc. is the larger business by last-quarter revenue ($10.0M vs $1.2M, roughly 8.3× BIOMERICA INC). Alpha Teknova, Inc. runs the higher net margin — -47.7% vs -109.1%, a 61.4% gap on every dollar of revenue. On growth, Alpha Teknova, Inc. posted the faster year-over-year revenue change (7.8% vs -26.0%). Over the past eight quarters, BIOMERICA INC's revenue compounded faster (9.1% CAGR vs 3.7%).
Biomerica Inc. is a global medical technology company that develops, manufactures and markets diagnostic test kits and related medical products. Its portfolio covers gastrointestinal conditions, infectious diseases, food intolerances and point-of-care testing solutions, serving clinical labs, healthcare providers and retail healthcare segments across North America, Europe and Asia.
Alpha Teknova, Inc. is a life sciences company that develops and manufactures specialized reagents, cell culture media, and custom laboratory solutions. It serves biopharmaceutical, molecular diagnostic, and academic research clients, primarily operating across the North American market to support drug discovery, diagnostic testing, and life science research workflows.
BMRA vs TKNO — Head-to-Head
Income Statement — Q2 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $10.0M |
| Net Profit | $-1.3M | $-4.8M |
| Gross Margin | 4.2% | 32.5% |
| Operating Margin | -113.5% | -46.2% |
| Net Margin | -109.1% | -47.7% |
| Revenue YoY | -26.0% | 7.8% |
| Net Profit YoY | -38.9% | 16.8% |
| EPS (diluted) | $-0.45 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $10.0M | ||
| Q3 25 | $1.4M | $10.5M | ||
| Q2 25 | $749.0K | $10.3M | ||
| Q1 25 | $1.1M | $9.8M | ||
| Q4 24 | $1.6M | $9.3M | ||
| Q3 24 | $1.8M | $9.6M | ||
| Q2 24 | $1.1M | $9.6M | ||
| Q1 24 | $1.0M | $9.3M |
| Q4 25 | $-1.3M | $-4.8M | ||
| Q3 25 | $2.0K | $-4.3M | ||
| Q2 25 | $-1.5M | $-3.6M | ||
| Q1 25 | $-1.2M | $-4.6M | ||
| Q4 24 | $-950.0K | $-5.7M | ||
| Q3 24 | $-1.3M | $-7.6M | ||
| Q2 24 | $-1.4M | $-5.4M | ||
| Q1 24 | $-1.9M | $-8.1M |
| Q4 25 | 4.2% | 32.5% | ||
| Q3 25 | 30.7% | 30.7% | ||
| Q2 25 | -33.0% | 38.7% | ||
| Q1 25 | 1.7% | 30.7% | ||
| Q4 24 | 26.7% | 23.0% | ||
| Q3 24 | 16.0% | 0.9% | ||
| Q2 24 | 2.1% | 29.2% | ||
| Q1 24 | -14.7% | 23.8% |
| Q4 25 | -113.5% | -46.2% | ||
| Q3 25 | -81.0% | -38.4% | ||
| Q2 25 | -209.1% | -32.9% | ||
| Q1 25 | -108.1% | -50.7% | ||
| Q4 24 | -60.7% | -60.7% | ||
| Q3 24 | -75.7% | -77.6% | ||
| Q2 24 | -136.6% | -53.0% | ||
| Q1 24 | -196.7% | -86.0% |
| Q4 25 | -109.1% | -47.7% | ||
| Q3 25 | 0.1% | -41.0% | ||
| Q2 25 | -206.1% | -34.7% | ||
| Q1 25 | -103.9% | -47.4% | ||
| Q4 24 | -58.1% | -61.7% | ||
| Q3 24 | -72.8% | -79.0% | ||
| Q2 24 | -127.1% | -55.8% | ||
| Q1 24 | -188.6% | -87.2% |
| Q4 25 | $-0.45 | $-0.08 | ||
| Q3 25 | $0.00 | $-0.08 | ||
| Q2 25 | $-0.99 | $-0.07 | ||
| Q1 25 | $-0.48 | $-0.09 | ||
| Q4 24 | $-0.06 | $-0.09 | ||
| Q3 24 | $-0.63 | $-0.15 | ||
| Q2 24 | $-2.57 | $-0.13 | ||
| Q1 24 | $-0.11 | $-0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | $21.3M |
| Total DebtLower is stronger | — | $13.1M |
| Stockholders' EquityBook value | $4.4M | $68.8M |
| Total Assets | $6.0M | $103.6M |
| Debt / EquityLower = less leverage | — | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.5M | $21.3M | ||
| Q3 25 | $3.1M | $22.1M | ||
| Q2 25 | $3.1M | $24.0M | ||
| Q1 25 | $3.1M | $26.3M | ||
| Q4 24 | $2.4M | $30.4M | ||
| Q3 24 | $2.8M | $31.7M | ||
| Q2 24 | $4.2M | $18.6M | ||
| Q1 24 | $5.3M | $21.6M |
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $13.1M | ||
| Q2 25 | — | $13.0M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | — | $9.4M | ||
| Q3 24 | — | $10.9M | ||
| Q2 24 | — | $12.3M | ||
| Q1 24 | — | $13.2M |
| Q4 25 | $4.4M | $68.8M | ||
| Q3 25 | $5.2M | $72.7M | ||
| Q2 25 | $4.1M | $76.1M | ||
| Q1 25 | $5.5M | $78.6M | ||
| Q4 24 | $5.1M | $82.4M | ||
| Q3 24 | $5.3M | $87.3M | ||
| Q2 24 | $6.6M | $78.9M | ||
| Q1 24 | $7.8M | $83.4M |
| Q4 25 | $6.0M | $103.6M | ||
| Q3 25 | $6.9M | $107.6M | ||
| Q2 25 | $5.9M | $110.5M | ||
| Q1 25 | $7.4M | $114.0M | ||
| Q4 24 | $7.3M | $118.8M | ||
| Q3 24 | $7.9M | $124.1M | ||
| Q2 24 | $9.3M | $115.4M | ||
| Q1 24 | $10.3M | $120.8M |
| Q4 25 | — | 0.19× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.17× | ||
| Q4 24 | — | 0.11× | ||
| Q3 24 | — | 0.12× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-991.0K | $-462.0K |
| Free Cash FlowOCF − Capex | — | $-810.0K |
| FCF MarginFCF / Revenue | — | -8.1% |
| Capex IntensityCapex / Revenue | — | 3.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-9.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-991.0K | $-462.0K | ||
| Q3 25 | $-268.0K | $-2.0M | ||
| Q2 25 | $-661.0K | $-2.1M | ||
| Q1 25 | $-1.0M | $-4.1M | ||
| Q4 24 | $-791.0K | $-936.0K | ||
| Q3 24 | $-1.3M | $-2.1M | ||
| Q2 24 | $-1.0M | $-2.8M | ||
| Q1 24 | $-1.8M | $-6.6M |
| Q4 25 | — | $-810.0K | ||
| Q3 25 | — | $-2.4M | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | — | $-4.3M | ||
| Q4 24 | — | $-1.5M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | $-1.1M | $-3.0M | ||
| Q1 24 | — | $-6.7M |
| Q4 25 | — | -8.1% | ||
| Q3 25 | — | -22.6% | ||
| Q2 25 | — | -22.4% | ||
| Q1 25 | — | -44.0% | ||
| Q4 24 | — | -16.2% | ||
| Q3 24 | — | -25.0% | ||
| Q2 24 | -95.5% | -30.7% | ||
| Q1 24 | — | -71.8% |
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 3.7% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | 2.1% | ||
| Q4 24 | — | 6.1% | ||
| Q3 24 | — | 3.5% | ||
| Q2 24 | 2.1% | 1.2% | ||
| Q1 24 | 0.0% | 1.2% |
| Q4 25 | — | — | ||
| Q3 25 | -134.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BMRA
Segment breakdown not available.
TKNO
| Lab Essentials | $6.8M | 68% |
| Clinical Solutions | $2.7M | 27% |
| Other | $435.0K | 4% |
